Cargando…

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins including tumor suppressors and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and aggressive lymphomas. Oral Selective Inhibitor of Nuclear Ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hing, Zachary A., Fung, Ho Yee Joyce, Ranganathan, Parvathi, Mitchell, Shaneice, El-Gamal, Dalia, Woyach, Jennifer A., Williams, Katie, Goettl, Virginia M., Smith, Jordan, Yu, Xueyan, Meng, Xiaomei, Sun, Qingxiang, Cagatay, Tolga, Lehman, Amy M., Lucas, David M., Baloglu, Erkan, Shacham, Sharon, Kauffman, Michael G., Byrd, John C., Chook, Yuh Min, Garzon, Ramiro, Lapalombella, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143172/ https://www.ncbi.nlm.nih.gov/pubmed/27323910 http://dx.doi.org/10.1038/leu.2016.136

Ejemplares similares

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
por: Mitchell, Shaneice, et al.
Publicado: (2021)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease
por: Zitzer, Nina C., et al.
Publicado: (2018)

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
por: Elgamal, Ola A., et al.
Publicado: (2020)

Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model
por: Cannon, Matthew, et al.
Publicado: (2021)

Correlation of CRM1-NES affinity with nuclear export activity
por: Fu, Szu-Chin, et al.
Publicado: (2018)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
por: Khan, Husain Yar, et al.
Publicado: (2019)

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
por: Yoshimura, Mariko, et al.
Publicado: (2014)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization
por: Pinarbasi, Emile S., et al.
Publicado: (2018)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation
por: Baumhardt, Jordan M., et al.
Publicado: (2020)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

Mechanism of karyopherin-β2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X)
por: Gonzalez, Abner, et al.
Publicado: (2021)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Nucleo-cytoplasmic transport as a therapeutic target of cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Importin-9 wraps around the H2A-H2B core to act as nuclear importer and histone chaperone
por: Padavannil, Abhilash, et al.
Publicado: (2019)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA
por: Frigault, M., et al.
Publicado: (2022)

XPO5 promotes primary miRNA processing independently of RanGTP
por: Wang, Jingjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c6bkgnhjtk49mpn1844cp0ab87